Payment overview · 2025
General Payments
$2,788.64
115 reported records · 22 companies
Healthcare provider profile · identity verified
David Fawks, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Psychiatric/Mental Health · VENICE, FL · NPI 1922094937
Verified facts
What the public records show
CMS Open Payments records show David Fawks, ARNP received $2,788.64 in general payments during 2025 across 115 reported records.
Neurocrine BioSciences, Inc. accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Aplenzin, Austedo Xr, Auvelity, Ingrezza, Loreev Xr, Rexulti, Trintellix, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Vraylar by this doctor in 2024.
Almatica Pharma LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOREEV XR as an associated drug or biological on 9621 records involving 4446 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Loreev Xr by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Auvelity by this doctor in 2024.
Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported APLENZIN as an associated drug or biological on 9096 records involving 3309 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Aplenzin by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Rexulti by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Trintellix by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $467.57 | 16.8% | 17 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $395.27 | 14.2% | 11 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $351.60 | 12.6% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $202.54 | 7.3% | 11 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $178.27 | 6.4% | 11 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $149.36 | 5.4% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $139.18 | 5.0% | 6 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $119.61 | 4.3% | 5 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $116.42 | 4.2% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $112.74 | 4.0% | 5 | 2025 |
| Noven Therapeutics, LLC | Unresolved — no canonical attribution shown | $105.24 | 3.8% | 6 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $87.82 | 3.1% | 4 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $86.14 | 3.1% | 5 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $69.34 | 2.5% | 3 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $53.68 | 1.9% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $45.24 | 1.6% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.36 | 1.1% | 2 | 2025 |
| Validus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $19.66 | 0.7% | 1 | 2025 |
| IDORSIA PHARMACEUTICALS US INC | Unresolved — no canonical attribution shown | $17.79 | 0.6% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.09 | 0.6% | 1 | 2025 |
| Neos Therapeutics, LP | Unresolved — no canonical attribution shown | $14.45 | 0.5% | 1 | 2025 |
| TMS NeuroHealth Centers Inc. | Unresolved — no canonical attribution shown | $11.27 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,788.64 | 115 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $467.57 | 17 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $395.27 | 11 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $351.60 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $317.45 | 17 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $202.54 | 11 | 2025 |
Source payment records
|
|||||
| ARISTADA Normalized: aristada |
Drug | Alkermes, Inc. | $190.22 | 9 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $149.36 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $119.61 | 5 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $116.42 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $112.74 | 5 | 2025 |
Source payment records
|
|||||
| Xelstrym Normalized: xelstrym |
Drug | Noven Therapeutics, LLC | $105.24 | 6 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $87.82 | 4 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $86.14 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $69.34 | 3 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $53.68 | 2 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $45.24 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $29.36 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| EQUETRO Normalized: equetro |
Drug | Validus Pharmaceuticals LLC | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| Quviviq Normalized: quviviq |
Drug | IDORSIA PHARMACEUTICALS US INC | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| Adzenys XR-ODT Normalized: adzenys xr odt |
Drug | Neos Therapeutics, LP | $14.45 | 1 | 2025 |
Source payment records
|
|||||
| TMS NeuroHealth Centers Inc. Normalized: tms neurohealth centers inc |
Device | TMS NeuroHealth Centers Inc. | $11.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| APLENZIN aplenzin |
2025 | Aplenzin | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| AUSTEDO XR austedo xr |
2025 | Austedo Xr | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Auvelity auvelity |
2025 | Auvelity | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LOREEV XR loreev xr |
2025 | Loreev Xr | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRINTELLIX trintellix |
2025 | Trintellix | 2024 | 61 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
84 | 14 |
| Almatica Pharma LLC Exact reporting entity; no affiliate inference |
2025 | LOREEV XR open payments reported associated product |
CMS Open Payments — General Payments 9621 supporting records · 4446 recipient NPIs · example record 1209929018 |
Loreev Xr · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | APLENZIN open payments reported associated product |
CMS Open Payments — General Payments 9096 supporting records · 3309 recipient NPIs · example record 1239973605 |
Aplenzin · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | TRINTELLIX open payments reported associated product |
CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266 |
Trintellix · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 407 | 98 |
| Clonazepam | Clonazepam | 362 | 85 |
| Trazodone Hcl | Trazodone Hcl | 336 | 84 |
| Duloxetine Hcl | Duloxetine Hcl | 330 | 76 |
| Lorazepam | Lorazepam | 290 | 76 |
| Lamotrigine | Lamotrigine | 287 | 58 |
| Quetiapine Fumarate | Quetiapine Fumarate | 267 | 57 |
| Sertraline Hcl | Sertraline Hcl | 234 | 54 |
| Buspirone Hcl | Buspirone Hcl | 217 | 58 |
| Bupropion Xl | Bupropion Hcl | 206 | 61 |
| Mirtazapine | Mirtazapine | 197 | 50 |
| Fluoxetine Hcl | Fluoxetine Hcl | 192 | 46 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 182 | 46 |
| Gabapentin | Gabapentin | 169 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 47 |
| Aripiprazole | Aripiprazole | 129 | 43 |
| Olanzapine | Olanzapine | 117 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 115 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 110 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 101 | 30 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 95 | 21 |
| Diazepam | Diazepam | 88 | 24 |
| Vilazodone Hcl | Vilazodone Hcl | 86 | 23 |
| Vraylar | Cariprazine Hcl | 84 | 14 |
| Lurasidone Hcl | Lurasidone Hcl | 82 | 19 |
| Ziprasidone Hcl | Ziprasidone Hcl | 80 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 71 | 27 |
| Eszopiclone | Eszopiclone | 69 | 12 |
| Risperidone | Risperidone | 68 | 11 |
| Doxepin Hcl | Doxepin Hcl | 67 | 24 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 66 | 20 |
| Oxcarbazepine | Oxcarbazepine | 66 | 16 |
| Trintellix | Vortioxetine Hydrobromide | 61 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 59 | 17 |
| Rexulti | Brexpiprazole | 59 | suppressed |
| Topiramate | Topiramate | 57 | 15 |
| Propranolol Hcl | Propranolol Hcl | 49 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 47 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 46 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | suppressed |
| Modafinil | Modafinil | 42 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 41 | suppressed |
| Ingrezza | Valbenazine Tosylate | 37 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 34 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 28 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Belsomra | Suvorexant | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Temazepam | Temazepam | 24 | suppressed |
| Austedo Xr | Deutetrabenazine | 23 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 22 | suppressed |
| Loreev Xr | Lorazepam | 20 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 20 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 15 | suppressed |
| Triazolam | Triazolam | 14 | suppressed |
| Fetzima | Levomilnacipran Hcl | 13 | suppressed |
| Aplenzin | Bupropion Hbr | 12 | suppressed |
| Fluvoxamine Maleate Er | Fluvoxamine Maleate | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Phenelzine Sulfate | Phenelzine Sulfate | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,788.64 · 115 records | Neurocrine BioSciences, Inc. | APLENZIN, ARISTADA, AUSTEDO XR, Adzenys XR-ODT, Auvelity, Azstarys, CAPLYTA, COBENFY, EQUETRO, FANAPT, HETLIOZ, INGREZZA, LOREEV XR, LYBALVI, Qelbree, Quviviq, REXULTI, SPRAVATO, TMS NeuroHealth Centers Inc., TONMYA, TRINTELLIX, VRAYLAR, Xelstrym | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Aplenzin play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error